Literature DB >> 16369980

Heparin-induced thrombocytopenia and thrombosis.

A Davoren1, R H Aster.   

Abstract

Heparin, employed clinically for more than 50 years, is still a widely used anticoagulant. Unfortunately, some patients given this agent develop thrombocytopenia and thrombosis. Because this side effect can have catastrophic consequences, it is imperative that all clinicians caring for patients who receive heparin have at least a basic understanding of its pathogenesis, diagnosis, and management. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16369980     DOI: 10.1002/ajh.20490

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

1.  84-year-old woman with hemodialysis-associated shortness of breath.

Authors:  Suraj Kapa; Qi Qian
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

2.  Utilization rates of enoxaparin and heparin in deep venous thrombosis prophylaxis after education and electronic order change at a single institution: a quality improvement study.

Authors:  Linda Hoang; Shahidul Islam; Alexander Hindenburg
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

3.  CalDAG-GEFI deficiency protects mice in a novel model of Fcγ RIIA-mediated thrombosis and thrombocytopenia.

Authors:  Moritz Stolla; Lucia Stefanini; Pierrette André; Timothy D Ouellette; Michael P Reilly; Steven E McKenzie; Wolfgang Bergmeier
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 4.  Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.

Authors:  Yacine Boulaftali; Paul R Hess; Mark L Kahn; Wolfgang Bergmeier
Journal:  Circ Res       Date:  2014-03-28       Impact factor: 17.367

5.  Acute post-cardiopulmonary bypass left atrial thrombosis after mitral valvuloplasty and left atrial thrombectomy.

Authors:  Dong-Hyup Lee; Tae-Eun Jung; Sang-Jin Park
Journal:  J Cardiothorac Surg       Date:  2012-01-11       Impact factor: 1.637

6.  PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

Authors:  Michael P Reilly; Uma Sinha; Pierrette André; Scott M Taylor; Yvonne Pak; Francis R Deguzman; Nisha Nanda; Anjali Pandey; Moritz Stolla; Wolfgang Bergmeier; Steven E McKenzie
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

7.  Protamine-induced immune thrombocytopenia.

Authors:  Atul Singla; Mia J Sullivan; Grace Lee; John Bartholomew; Samir Kapadia; Richard H Aster; Brian R Curtis
Journal:  Transfusion       Date:  2013-02-05       Impact factor: 3.157

8.  Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.

Authors:  John R Bartholomew; Carolynn E Pietrangeli; Marcie J Hursting
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report.

Authors:  Ravish A Shah; Adnan Musthaq; Nancy Khardori
Journal:  J Med Case Rep       Date:  2009-06-26

Review 10.  Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.

Authors:  R H Aster; B R Curtis; J G McFarland; D W Bougie
Journal:  J Thromb Haemost       Date:  2009-04-02       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.